We’re delighted to announce that we’ve achieved milestones for two programmes in our Sanofi collaboration. Both programmes have demonstrated our ability to design highly differentiated molecules, which have the potential to produce best-in-class assets. We will receive an aggregate of $15 million for achieving these milestones and are eligible for over $600 million in additional milestone payments for the two programmes, as well as high-single-digit to mid-teen royalties. Learn more here: https://lnkd.in/ejya2zqW
Exscientia
Biotechnology Research
Oxford, Oxfordshire 48,611 followers
Better drugs, faster
About us
Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.
- Website
-
https://www.exscientia.com
External link for Exscientia
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Oxford, Oxfordshire
- Type
- Public Company
- Founded
- 2012
- Specialties
- Artificial Intelligence, AI Drug Discovery, Tech Enabled Drug Development, Precision Medicine, Pharmaceuticals, and Technology
Locations
Employees at Exscientia
Updates
-
Interesting article from Genetic Engineering & Biotechnology News on AI in Drug Design, including thoughts from Thorsten Nowak, Exscientia’s VP of Medicinal Chemistry. Thorsten discusses how coupling predictive modelling and AI-driven design with automated experimentation, alongside a multiparametric approach to drug design, allows Exscientia to secure optimised solutions to problems and find potentially better drugs, more efficiently: https://lnkd.in/gKuQhEaz #AI #drugdesign #automation #medicinalchemistry
-
We’re excited to announce that we’ll be presenting new preclinical data for both our LSD1 and MALT1 inhibitor programmes at the upcoming ENA Symposium in October 2024. Learn more here: https://lnkd.in/eXv7Khw4 Our posters highlight: - The combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies - The efficacy of EXS74539 in a preclinical AML model, with limited impact on platelet levels, and the identification of PD biomarkers related to LSD1 inhibitor treatment #ENASymp24 #drugdiscovery #oncology
-
We’re delighted that Nikolaus Krall, EVP Precision Medicine, has been named as an inspiring leader in the PharmaVoice 100 list. Nikolaus has been instrumental in the advancement of patient-first AI and the precision medicine platform at Exscientia. Congratulations Nikolaus! #LifeSciences #Pharma #PharmaVoice100
I’m excited to share that I’ve been recognised on the PharmaVoice 100 list as an inspiring leader in the life-sciences space! It’s an honour to make this list alongside so many of my talented peers in the life sciences industry. Check out the full list here: https://lnkd.in/e4-QG6yb
-
Laura Thompson, one of our Senior Scientists, presented yesterday at Discovery on Target on the automation of a cellular biosensor assay to allow for efficient hit compound screening. � Download the poster to learn how automating cellular assays can potentially reduce the�cost, labour and timelines for drug discovery programmes: https://lnkd.in/eM8gqM49 �� #automation #drugdiscovery�
I'm excited to be presenting a poster titled: "Hands-off Screening with Cells: Automating a Cellular Biosensor for Streamlined and Efficient Hit Compound Screening" at Discovery On Target today. Traditional manual cellular screening assays often demand substantial scientist time and consumable resources, while being prone to variability in transfection efficiency, which can affect data reproducibility. Our poster showcases how we transitioned a continuous culture screening assay to an "assay-ready" cell format and leveraged Exscientia's automation suite to deliver an end-to-end automated assay, freeing up valuable scientist resource and increasing hit compound screening efficiency. I'm excited to share our work, connect with fellow scientists, and discuss the latest trends in emerging targets and technologies. If you're attending, feel free to stop by and say hello! #Exscientia #BostonDOT24
-
Otto Morris, Senior Biological Data Scientist, is presenting today at ELRIG UK Drug Discovery on DepExML, our explainable machine learning pipeline for identifying predictive biomarkers from dependency datasets. Download our poster to learn how DepExML generates actionable insights into complex cancer biology, providing translatable opportunities to develop novel, potential�first-in-class drugs to address clinical unmet needs in precisely defined patient groups. https://lnkd.in/erpu77xx � � #elrig #elrigdd24 #drugdiscovery #machinelearning�
I am excited to present a poster at the ELRIG UK Drug Discovery 2024 conference on behalf of the Exscientia Biological Data Science Team. Our poster outlines "DepExML: An explainable machine learning pipeline for context-aware biomarker discovery". Using cell line omics data as input features (e.g. mRNA expression, mutation status, etc.), DepExML systematically identifies predictive biomarkers from dependency datasets, e.g. CRISPR screens. The resulting models achieve state-of-the-art performance yet are fully interpretable, enabling the examination of single and multi-gene genetic interactions at up to single-cell line resolution. DepExML thus supports Exscientia's precision oncology programme by identifying novel, actionable target-disease-biomarker hypotheses. #Exscientia�#ELRIG
-
Our collaborators from Professor Millán’s Lab at Sanford Burnham Prebys presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting today, showing for the first time that ENPP1 is a druggable target for late-onset hypophosphatasia (HPP), a rare and often severe disease. In in vivo studies using our AI-designed tool ENPP1 inhibitor compound, REV101, pyrophosphate (PPi) was significantly lowered to normal concentrations and improvements in mineralisation of bones were shown, which are key functional readouts for disease pathology. Together with Rallybio, we’re developing an ENPP1 inhibitor with improved properties compared with REV101 as a differentiated therapy to address unmet need in patients with HPP. We look forward to sharing more information with you soon. Download our ASBMR poster here: https://bit.ly/EXAI_ASBMR #rarediseases #AI #drugdiscovery #ASBMR2024
-
Mason Burlage, Cheminformatics Research Scientist, is presenting today on SALSA – our new approach to virtual chemical space exploration. Download the poster to read how SALSA has the potential to accelerate drug discovery. It enables the efficient exploration of ultra-large chemical spaces, leading to the identification of novel and effective therapeutics: https://lnkd.in/eZAUM6ij #EuroQSAR #AI #drugdiscovery
Excited to share my poster on our generative molecular design method, SALSA, at EuroQSAR 2024 in Barcelona! SALSA generates a synthetically-tractable, ultra-large library derived from multiple R-group enumeration. It then screens this chemical space though a novel, model-guided active-learning workflow which selects constituent synthons for enumeration. This architecture has been shown to be sample-efficient across user-defined multi-parameter objectives and scalable to chemical spaces that, if enumerated, are trillions of molecules in size. Looking forward to the rest of the conference this week!
-
Many thanks to Amazon Web Services (AWS), for highlighting our work in reimagining drug discovery, enabled by their cloud services! Read about our innovative Design-Make-Test-Learn cycles, integrating generative AI drug design and robotic lab automation and built on AWS, to help improve the efficiency and effectiveness of drug discovery. #DMTL #automation #AI #generativeAI
Developing effective therapies at a fraction of the cost with #generativeAI. 🔬💡👉 https://go.aws/4dMZWxj Exscientia leverages generative AI on #AWS to reduce bottlenecks, accelerate development & revolutionize drug discovery.
AWS Customer Story - Exscientia
-
If you’re attending the 24th EuroQSAR this week, make sure to catch Exscientia’s presentations. Our CTO, John Overington, will be presenting a plenary lecture (PL12) on emerging AI approaches to drug discovery. We’ll also have posters detailing our drug-induced liver injury models and scalable active learning over synthon space. Review the programme here: https://lnkd.in/ebsh4UhP #EuroQSAR #AI #drugdiscovery